Impax to help Wyeth promote Pristiq; Pfizer expands discount program for uninsured;

> Impax Pharmaceuticals said it has agreed to use its neurology-focused sales force to co-promote Wyeth's antidepressant Pristiq. Release

> Pfizer's prescription-savings program, Together Rx Access, has expanded its eligibility income levels to allow nearly 90 percent of uninsured Americans to save on the medicines they need. Release

> GlaxoSmithKline has dropped the price of its human papillomavirus vaccine Cervaris by 30 percent in Singapore. Report

> A Citi Investment Research analyst upgraded shares of Eli Lilly & Co. to "Buy", saying the company will be able to launch its blood thinner Effient in the second quarter of 2009, and predicting annual sales of about $2 billion by 2015. Report

> The Indian pharma industry is now likely to clock 12 percent to 13 percent growth in 2000, rather than a previously expected 15 percent, because of the global economic meltdown, a research firm said. Report

> Chinese health authorities are investigating baby products made by Johnson & Johnson in response to a U.S. consumer group's charges, disputed by the company, that some chemicals contained in the products could cause cancer. Report

> AstraZeneca's Christiana, Delaware, site was one of four pharmaceutical plants to receive the Environmental Protection Agency's Energy Star ranking, part of a federal effort to recognize the nation's most energy-efficient businesses. Report

> Warner Chilcott said that one of its subsidiaries and Mayne Pharma have filed a second lawsuit against Impax Laboratories in an attempt to block the generics maker's version of their antibiotic drug Doryx. Release

> Cardinal Health has opened a new facility in Omaha, Nebraska, to manufacture radiopharmaceuticals, giving local doctors new diagnostic and treatment tools. Report

> A new survey of the state of Canada's biotech industry by Peter Brenders paints a bleak picture. Report

> Merck KGaA is funneling $19 million into a joint research project between one of its subsidiaries--EMD Serono--and the National Multiple Sclerosis Society to fast-track new therapies for MS. Report

> Biotech lobbyists loudly cheered a newly-introduced bill that offers 12 years of market exclusivity to branded biologics before they have to confront a generic competitor. Report

> San Bruno, CA-based Numerate has wrapped a $5.5 million Series B round to help finance its drug engineering work. Report

> Will the Wyeth buyout derail Pfizer's R&D makeover? Report

And Finally... A U.K. teen was suspended from community college for distributing Pfizer's sildenafil citrate to her fellow students. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.